A Pfizer-Wyeth Merger Isn't the Cure-AllCatherine Arnst
Pfizer (PFE) has been hinting for months that it was in the market for a major acquisition to bolster its sagging fortunes, and it may have found its target. The Wall Street Journal (NWS) reported on Jan. 23 that New York-based Pfizer, the world's largest drugmaker, is in talks to buy Wyeth (WYE), the ninth largest, for as much as $60 billion in stock and cash. Neither company will comment on the report, but that hasn't stopped analysts, investors, and industry bloggers from mulling over the potential of a combined "Pfyeth."
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.